Company Overview of Rubicon Genomics, Inc.
Rubicon Genomics, Inc. engages in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for research and clinical testing. It develops molecular biology tools for the genetic, epigenetic, and expression analysis of clinical samples to facilitate gene-based research, drug development, diagnostics, and forensics. The company’s products include Whole Genome Amplification (WGA) kit, which offers reproducible WGA from single cells; C-WGA that delivers reproducible WGA from fixed and other degraded samples; C-Whole Transcriptome Amplification (WTA) for that provides reproducible WTA from fix...
4355 Varsity Drive
Ann Arbor, MI 48108
Founded in 2000
Key Executives for Rubicon Genomics, Inc.
Co-Founder and Chief Scientific Officer
Director of Sales and Marketing
Compensation as of Fiscal Year 2014.
Rubicon Genomics, Inc. Key Developments
Rubicon Genomics, Inc. Expands Distribution in Europe and Asia
Dec 12 13
Rubicon Genomics, Inc. announced that it has partnered with additional distributors globally to expand availability of its products, including ThruPLEX -FD Prep Kits and PicoPLEX-WGA Kits. Three new distribution partnerships have been signed for Europe. They include Amplitech for France, HPST for the Czech Republic and LuBio Science for Switzerland. Rubicon also completed new distribution agreements in Asia and the Middle East. They include Recenttec for Japan, Prisma Biotech for Taiwan and S.M. Chemical for Thailand. Custom Science will provide distribution services to Australia and New Zealand. A well-established local biomedical distributor is supporting sales of Rubicon's products in Qatar. ThruPLEX-FD Prep Kits for Illumina NGS platforms streamline library preparation for fragmented DNA/cDNA and reduce sample input amounts to picogram levels. ThruPlex-FD's patented technology delivers a highly efficient and user-friendly process that takes place in a single tube in less than 2 hours. ThruPLEX-FD provides consistent and reliable results for applications including DNA-seq, RNA-seq and ChiP-seq and is especially useful for clinical samples such as plasma and FFPE.
Utility of Rubicon Genomics, Inc.s' ThruPLEX(TM)-FD Kit Validates in Study Showing Liquid Biopsy
Sep 30 13
Rubicon Genomics, Inc. reported that its ThruPLEX(TM) -FD Prep Kits contributed to the success of a breakthrough study recently published in Nature that showed that genomic data extracted from the plasma of cancer patients can be used to track drug resistance and potentially guide treatment. The proof-of-principle study showed that by sequencing tumor exomes extracted from patient plasma samples, it is possible to track how metastatic cancer evolves to acquire resistance to cancer therapy. In patients with advanced breast, lung and ovarian cancers, the researchers derived tumor sequences using plasma samples taken during multiple courses of treatment. They were able to identify mutations associated with the emergence of resistance to cancer drugs including cisplatin, tamoxifen and gefitinib. The authors concluded that this non-invasive 'liquid biopsy,' based on tumor DNA that is released into the circulation, offers important advantages and could complement current invasive biopsy methods that can be uncomfortable and costly. ThruPLEX-FD Prep Kits are designed to provide sensitive and consistent sequencing from challenging samples containing small amounts of degraded DNA with minimum hands-on time. They leverage Rubicon's patented DNA repair and ligation methods to deliver more rapid and sensitive sequencing of plasma, formalin-fixed, ChIP and other fragmented DNA samples with increased throughput. This study illustrates how ThruPLEX-FD can be a valuable tool for generating the high quality genomic information that is essential for personalized medicine. For this study, the scientists used ThruPlex-FD to prepare libraries from very small quantities of circulating DNA extracted from plasma (as small as 2.3 ng of DNA.) After enriching for the exome fraction, pair-end sequencing of the samples were performed on an Illumina HiSeq 2500. ThruPLEX-FD is a streamlined single tube, three-step process that eliminates intermediate purifications, transfers, columns or gels. This decreases the likelihood of experimental variability, bias and contamination. DNA is sequencing-ready in two hours with as little as 15 minutes of hands-on time. A technician can prepare 192 ThruPLEX samples per day--a 15-fold increase in productivity compared to other methods. ThruPLEX-FD is designed and validated for use with samples as small as 50 picograms of human DNA and can be used with plasma, FFPE, or fragmented gDNA in FFPE for DNA-seq, RNA-seq and ChIP-seq applications. ThruPLEX-FD is currently available as 12 or 48-reaction, 12-index kits for sequencing on Illumina(R) HiSeq(R), MiSeq(R) and Genome Analyzer instruments. ThruPLEX-FD kits are being developed for additional formats and platforms.
Diagenode Sa to Integrate Rubicon's ThruPLEX(TM) Technology
Nov 1 12
Rubicon Genomics, Inc. announced that it has partnered with Diagenode SA to integrate Rubicon's ThruPLEX(TM) technology into Diagenode's epigenetics platforms to increase the efficiency and quality of DNA sample preparation for chromatin immunoprecipitation (ChIP) applications. The new agreement allows Diagenode to incorporate the Rubicon ThruPLEX-FD technology into its new MicroPLEX Library Preparation Kit for ChIP-seq studies requiring very small amounts of sample. Diagenode's products increase the efficiency and speed of the process used to precipitate and recover DNA for ChIP applications from very small amounts of chromatin. The combination of these two patented technologies will decrease the time and labor needed for ChIP-sequencing by almost 10 hours and provide researchers with high quality ChIP-seq and ChIP-chip results from small samples, reducing the number of cells needed to conduct ChIP analyses by a minimum of 100-fold.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|